Author, date and country | Patient group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
---|---|---|---|---|---|
Migliardi JR et al. 1994 | 4 studies comprising 1811 patients. Outpatients aged 18-65 who reported an average of 6-7 tension-type headaches per month in the previous year that responded to OTC analgesics were included. Patient were randomised to receive 2 of either placebo, acetaminophen (APAP) alone, or acetaminophen/aspirin/caffeine (AAC) combination. One medication was used for 2 episodes, and then the other medications was given for use for another 2 episodes. | Randomised, double-blind, two-period crossover studies | Patient-reported pain intensity and pain relief using 4 and 5 point ordinal scales respectively | AAC showed significantly greater pain intensity difference, pain relief and total pain relief (P<0.001) | Dietary caffeine was only limited within 4hr study window. No comparison of the same analgesic with and without caffeine. |
Diamond et al. 2001 | 385 adult patients with history of acute TTH. Patients were given single-dose of ibuprofen and caffeine, ibuprofen alone, caffeine alone or placebo. Took medication when experienced an at least moderate severity tension-type headache. | Randomised, double-blind, parallel, single-dose, placebo-controlled trial | Patient-measured time to first onset of perceptible pain relief and first onset of meaningful pain relief. | Significantly more patients achieved meaningful pain relief with ibuprofen + caffeine than all other groups. Meaningful pain relief was achieved significantly quicker with ibuprofen + caffeine compared to placebo or ibuprofen alone | Dietary caffeine only limited in 4 hours prior to onset of headache |
Patient-rated pain relief and pain intensity | Ibuprofen + caffeine showed significantly greater pain relief compared to all other treatments (p<0.05) | ||||
Pini et al. 2008 | 93 patients aged 18-65 with history of TTH. Treated 3 consecutive TTH attack with the 3 different study medications (paracetamol 1g + caffeine 130mg (PCF), naproxen 550mg (NAP), or placebo (PLA)). Patients were randomised to 6 different sequences of treatment. | Multicentre, randomised, double-blind, double-dummy, crossover, placebo-controlled trial | Patient-reported pain intensity and pain relief at using 4- and 5-point scales respectively, at 1, 2, 3 and 4 hr post-ingestion | Both PCF and NAP achieved significantly better pain intensity difference and total pain relief compared to placebo (p<0.05). PCF and NAP. No significant difference between PCF and NAP. | No comparison of the same analgesic with and without caffeine. Sponsored by Angelini Farmaceutici. |
Goldstein et al. 2014 | 660 adult patients with diagnosis of migraines. Randomised to receive single dose containing acetaminophen/aspirin/caffeine (AAC), ibuprofen (IB), or placebo. | Multicentre, double-blind, randomised, parallel-group, placebo-controlled, single-dose study | Subjective pain intensity, pain relief, functional disability, nausea, vomiting, photo/phonophobia at intervals for 3hr post-ingestion | AAC achieved significantly faster onset of meaningful relief than IB. AAC showed significantly greater total pain relief and pain intensity difference than both IB and placebo (p<0.05). No consistent significant difference between AAC and IB in associated features and functional disability | No comparison of same analgesic with/without caffeine. |
Diener et al. 2005 | 1743 adult patients who met diagnostic criteria for TTH or migraine. Three independent headache episodes treated. First episode treated with patient’s usual non-prescription analgesic. Randomised to treat following 2 episodes with either aspirin+paracetamol+caffeine, aspirin+paracetamol, aspirin alone, paracetamol alone, caffeine alone, or placebo. | Randomised, placebo-controlled, double-blind, multi-centre, parallel group trial. | Primary endpoint was time to 50% pain relief based on patient-rated intensity using visual analogue scale for 4hr post-ingestion. | ASA+PAR+CAF was significantly superior to all other treatments (p<0.05). | |
Jafari et al. 2018 | 60 adult patients with diagnosed migraines. 2 medications prescribed for 4 consecutive episodes - ibuprofen 400mg or acetaminophen+aspirin+caffeine. | Double-blind clinical trial | Pain perception using 11-point Box Scale recorded prior to dose, at 2hr and 6hr. | Pain severity significantly lower in those taking AAC (p<0.05) at 2hr and 6hr post-dose. | Treatment protocol unclear. Not placebo controlled. Results do not take pre-dose pain level into account. |